{"id":5825,"date":"2025-05-15T08:46:45","date_gmt":"2025-05-15T08:46:45","guid":{"rendered":"https:\/\/synthelis.com\/?p=5825"},"modified":"2025-05-28T13:17:12","modified_gmt":"2025-05-28T13:17:12","slug":"cell-free-production-of-adeno-associated-virus-protein-particles","status":"publish","type":"post","link":"https:\/\/synthelis.com\/en\/cell-free-production-of-adeno-associated-virus-protein-particles\/","title":{"rendered":"Cell-free production of adeno-associated virus protein particles"},"content":{"rendered":"

[et_pb_section fb_built=”1″ _builder_version=”4.27.4″ _module_preset=”default” background_color=”#FFFFFF” custom_margin=”0px||||false|false” custom_padding=”||0px||false|false” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ _module_preset=”default” width=”100%” min_height=”222.8px” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”PT Serif||||||||” text_text_color=”#000000″ text_font_size=”17px” text_line_height=”1.8em” custom_padding=”||0px|||” global_colors_info=”{}”]<\/p>\n

Cell-free production of adeno-associated virus protein particles \u2013 Expanded horizons for gene therapy and vaccine development <\/strong><\/span><\/p>\n

Virus-like proteins (VLPs) are non-infectious polymeric nanoparticles formed from virus-coat proteins but deprived of genetic material. These features have enabled their successful use in several applications such as vaccines, gene therapy, and drug delivery systems [1]. Among the diverse VLPs developed so far, recombinant adeno-associated viruses (rAAVs) are increasingly used in gene therapy and vaccine development due to their low immunogenicity and lack of pathogenicity [2]. AAVs are nonenveloped single-stranded DNA viruses, and their genome encodes for three structural capsid proteins VP1, VP,2, and VP3. VP3 can self-assemble into capsids without the other capsid proteins.\u00a0<\/strong><\/span><\/p>\n

<\/strong><\/p>\n

 <\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.27.4″ _module_preset=”default” width=”100%” max_width=”2560px” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”http:\/\/synthelis.com\/wp-content\/uploads\/2025\/05\/AAV-.webp” alt=”adeno-associated virus protein particles – Synthelis Biotech ” title_text=”AAV protein particles” force_fullwidth=”on” _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.16″ _module_preset=”default” width=”100%” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”PT Serif||||||||” text_text_color=”#000000″ text_font_size=”17px” text_line_height=”1.8em” header_2_font=”PT Serif|700|||||||” header_2_font_size_tablet=”” header_2_font_size_phone=”24px” header_2_font_size_last_edited=”on|desktop” global_colors_info=”{}”]<\/p>\n

Limitations of Traditional rAAV Production\u00a0<\/strong><\/h2>\n

[\/et_pb_text][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”PT Serif||||||||” text_text_color=”#000000″ text_font_size=”17px” text_line_height=”1.8em” global_colors_info=”{}”]<\/p>\n

Traditionally, rAAVs have been produced in cell-based systems using mammalian, insect or bacterial cell lines, but these methods are time-consuming and have high costs, generating low titres of proteins in impure forms [3].<\/strong><\/span><\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.16″ _module_preset=”default” width=”100%” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”PT Serif||||||||” text_text_color=”#000000″ text_font_size=”17px” text_line_height=”1.8em” header_2_font=”PT Serif|700|||||||” header_2_font_size_tablet=”” header_2_font_size_phone=”24px” header_2_font_size_last_edited=”on|desktop” global_colors_info=”{}”]<\/p>\n

Cell-Free Production as an Alternative Approach\u00a0<\/strong><\/h2>\n

[\/et_pb_text][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”PT Serif||||||||” text_text_color=”#000000″ text_font_size=”17px” text_line_height=”1.8em” global_colors_info=”{}”]<\/p>\n

Cell-free production emerges as a valuable alternative for rAAV synthesis, providing rapid production<\/strong><\/span> with a simple workflow. Besides, due to its open nature, it can be easily manipulated to adapt to the protein of interest, by introducing enzymes<\/strong><\/span> and post-translational modifications<\/strong><\/span> that may not be feasible in prokaryotic cell-based systems.\u00a0<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.16″ _module_preset=”default” width=”100%” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”PT Serif||||||||” text_text_color=”#000000″ text_font_size=”17px” text_line_height=”1.8em” header_2_font=”PT Serif|700|||||||” header_2_font_size_tablet=”” header_2_font_size_phone=”24px” header_2_font_size_last_edited=”on|desktop” global_colors_info=”{}”]<\/p>\n

Recent Advances in Cell-Free rAAV Synthesis\u00a0<\/strong><\/h2>\n

[\/et_pb_text][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”PT Serif||||||||” text_text_color=”#000000″ text_font_size=”17px” text_line_height=”1.8em” global_colors_info=”{}”]<\/p>\n

A recently proposed cell-free method for the synthesis of rAAVs clearly demonstrates the advantages of cell-free protein synthesis (CFPS) for this type of protein.<\/strong><\/span> The method consisted on an E. coli-based cell-free system for the production of rAAV serotype 5 VP3 VLPs (rAAV5 VP3 VLPs) (Figure 1) [4].<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.27.4″ _module_preset=”default” width=”100%” custom_margin=”||30px||false|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”http:\/\/synthelis.com\/wp-content\/uploads\/2025\/05\/Cell-free-production-purification-and-characterization-of-recombinant-AAV5-VP3-VLPs.webp” alt=”Cell-free production, purification and characterization of recombinant AAV5 VP3 VLPs- Synthelis Biotech ” title_text=”Cell-free production, purification and characterization of recombinant AAV5 VP3 VLPs – Synthelis Biotech ” _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”|||0px|false|false” custom_padding=”||0px|0px|false|false” global_colors_info=”{}”][\/et_pb_image][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”PT Serif||||||||” text_text_color=”#000000″ text_font_size=”17px” text_line_height=”1.8em” global_colors_info=”{}”]<\/p>\n

Figure 1 \u2013 Cell-free production, purification and characterization of recombinant AAV5 VP3 VLPs. Reproduced from [4].<\/em><\/p>\n

[\/et_pb_text][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”PT Serif||||||||” text_text_color=”#000000″ text_font_size=”17px” text_line_height=”1.8em” global_colors_info=”{}”]<\/p>\n

The authors used an E. coli cell-free lysate generated using BL21 Star, and T7 RNA polymerase was supplemented in addition to the endogenous T7 RNA polymerase in the cell lysate to increase protein yields<\/strong><\/span>. Constructs with or without Strep-tag II were expressed (Figure 2).\u00a0<\/p>\n

[\/et_pb_text][et_pb_image src=”http:\/\/synthelis.com\/wp-content\/uploads\/2025\/05\/AAV5-VP3-gene-designs-that-were-expressed-in-the-cell-free-system.webp” alt=”AAV5 VP3 gene designs that were expressed in the cell-free system – Synthelis Biotech ” title_text=”AAV5 VP3 gene designs that were expressed in the cell-free system” _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”|||0px|false|false” custom_padding=”||0px|0px|false|false” global_colors_info=”{}”][\/et_pb_image][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”PT Serif||||||||” text_text_color=”#000000″ text_font_size=”17px” text_line_height=”1.8em” global_colors_info=”{}”]<\/p>\n

Figure 2 \u2013 AAV5 VP3 gene designs that were expressed in the cell-free system. Reproduced from [4].\u00a0<\/em><\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.16″ _module_preset=”default” width=”100%” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”PT Serif||||||||” text_text_color=”#000000″ text_font_size=”17px” text_line_height=”1.8em” header_2_font=”PT Serif|700|||||||” header_2_font_size_tablet=”” header_2_font_size_phone=”24px” header_2_font_size_last_edited=”on|desktop” global_colors_info=”{}”]<\/p>\n

Optimization of rAAV5 VP3 Production\u00a0<\/strong><\/h2>\n

[\/et_pb_text][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”PT Serif||||||||” text_text_color=”#000000″ text_font_size=”17px” text_line_height=”1.8em” global_colors_info=”{}”]<\/p>\n

Protein produced after 16 h CFPS was successfully identified by Western blot, using the primary antibody B1 which recognizes unassembled monomeric AAV capsid protein. The impact of temperature on the production of soluble protein was assessed by testing temperatures from 18 \u00b0C to 37 \u00b0C, and it was found that lower temperatures favored the synthesis of the soluble protein, with the untagged variant containing around 90% more soluble protein at 18 \u00b0C than at 37 \u00b0C. This could be due to increased protein misfolding at higher temperatures.\u00a0<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.16″ _module_preset=”default” width=”100%” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”PT Serif||||||||” text_text_color=”#000000″ text_font_size=”17px” text_line_height=”1.8em” header_2_font=”PT Serif|700|||||||” header_2_font_size_tablet=”” header_2_font_size_phone=”24px” header_2_font_size_last_edited=”on|desktop” global_colors_info=”{}”]<\/p>\n

Purification and Characterization of rAAV5 VP3 VLPs\u00a0<\/strong><\/h2>\n

[\/et_pb_text][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”PT Serif||||||||” text_text_color=”#000000″ text_font_size=”17px” text_line_height=”1.8em” global_colors_info=”{}”]<\/p>\n

Affinity chromatography of N-terminally Strep(II)-tagged VP3 allowed the efficient isolation of the variant with minimal processing and enabled further characterization of the protein particles. The fact that the protein was largely produced in soluble form facilitated its purification<\/strong>.<\/span> The estimated production yield was 2.98e9 capsids\/mL of cell-free reagent, and the obtained particles had ~20 nm diameter, as expected for an AAV5 particle. The biological activity of the produced AAV5 VP3 VLPs was evaluated by testing their internalization into HeLa cells, and it was shown that the cell-free produced particles were efficiently internalized, meaning that they had the appropriate morphology for receptor-mediated endocytosis.\u00a0<\/strong><\/span><\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.16″ _module_preset=”default” width=”100%” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”PT Serif||||||||” text_text_color=”#000000″ text_font_size=”17px” text_line_height=”1.8em” header_2_font=”PT Serif|700|||||||” header_2_font_size_tablet=”” header_2_font_size_phone=”24px” header_2_font_size_last_edited=”on|desktop” global_colors_info=”{}”]<\/p>\n

Potential Improvements for Enhanced Production\u00a0<\/strong><\/h2>\n

[\/et_pb_text][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”PT Serif||||||||” text_text_color=”#000000″ text_font_size=”17px” text_line_height=”1.8em” global_colors_info=”{}”]<\/p>\n

According to the authors, the relatively low purified capsid titers obtained can be increased by using refined purification techniques and by making adjustments in the cell-free system, namely by incorporating cofactors and additives to improve yield and capsid assembly. The cell-free method also offers the possibility for cargo loading or in vitro<\/em> gene packaging after capsid assembly<\/strong>.<\/span> Furthermore, the developed cell-free system constitutes a valuable high-throughput screening tool for alternative rAAV serotypes and mutants, facilitating the rapid prototyping of self-assembling particles.<\/strong><\/span><\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.16″ _module_preset=”default” width=”100%” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”PT Serif||||||||” text_text_color=”#000000″ text_font_size=”17px” text_line_height=”1.8em” header_2_font=”PT Serif|700|||||||” header_2_font_size_tablet=”” header_2_font_size_phone=”24px” header_2_font_size_last_edited=”on|desktop” global_colors_info=”{}”]<\/p>\n

Broader Applications of CFPS for VLP Production\u00a0<\/strong><\/h2>\n

[\/et_pb_text][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”PT Serif||||||||” text_text_color=”#000000″ text_font_size=”17px” text_line_height=”1.8em” global_colors_info=”{}”]<\/p>\n

In a more general sense, the advantageous application of cell-free synthesis for the production of VLPs has been widely proved in diverse applications such as the production of hepatitis B core VLPs [5,6] and human noroviruses VLPs [7] to be used as vaccine candidates.
The developed cell-free systems for VLP production showed improved performance over cell-based methods, facilitating the rapid screening of protein variants<\/strong>.<\/span>
Additionally, CFPS enables better control of the reaction conditions, namely the pH and the redox state for the formation of disulfide bonds<\/strong>,<\/span> which is a critical aspect in VLP synthesis, affecting the stability of the synthesized particles [8]. Furthermore, in cell-free systems, VLPs are purified in a single step, significantly reducing the cost of production [9] and the production time [5,7]<\/strong>. <\/span>
CFPS has allowed several improvements in VLP synthesis, such as surface functionalization of VLPs by direct conjugation using azide-alkyne click chemistry [10], expansion in VLP bioactivity [11], reduction of VLP intrinsic immunogenicity and increase in VLP solubility and assembly [12].\u00a0<\/strong><\/span><\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.16″ _module_preset=”default” width=”100%” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”PT Serif||||||||” text_text_color=”#000000″ text_font_size=”17px” text_line_height=”1.8em” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]<\/p>\n

Written by Lu\u00edsa Silva, PhD and scientific expert.<\/em><\/o:p><\/span><\/p>\n

[\/et_pb_text][et_pb_text _builder_version=”4.16″ _module_preset=”default” text_font=”PT Serif||||||||” text_text_color=”#000000″ text_font_size=”17px” text_line_height=”1.8em” header_2_font=”PT Serif|700|||||||” header_2_font_size_tablet=”” header_2_font_size_phone=”24px” header_2_font_size_last_edited=”on|phone” global_colors_info=”{}”]<\/p>\n

Synthelis<\/h2>\n

[\/et_pb_text][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”PT Serif||||||||” text_text_color=”#000000″ text_font_size=”17px” text_line_height=”1.8em” global_colors_info=”{}”]<\/p>\n

\n

With over more than 15 years of experience in cell-free technology, the Synthelis team can assist you if you wish to test VLP production using a cell-free system. Feel free to contact us if you have such a project.\u00a0<\/span><\/p>\n<\/blockquote>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_2,1_2″ _builder_version=”4.21.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_2″ _builder_version=”4.21.0″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_column][et_pb_column type=”1_2″ _builder_version=”4.21.0″ _module_preset=”default” global_colors_info=”{}”][dnxte_button button_text=”Talk to us” button_link=”@ET-DC@eyJkeW5hbWljIjp0cnVlLCJjb250ZW50IjoicG9zdF9saW5rX3VybF9wYWdlIiwic2V0dGluZ3MiOnsicG9zdF9pZCI6IjI2NCJ9fQ==@” dnxt_button_alignment=”right” _builder_version=”4.27.4″ _dynamic_attributes=”button_link” _module_preset=”default” btn_fonts_text_color=”#EDE8EC” background_color=”#4D1749″ global_colors_info=”{}”][\/dnxte_button][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.16″ _module_preset=”default” background_color=”#FFFFFF” custom_padding=”||0px||false|false” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ _module_preset=”default” width=”100%” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_divider color=”#D2C6D2″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_divider][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”PT Serif||||||||” text_text_color=”#000000″ text_font_size=”17px” text_line_height=”1.8em” header_2_font=”PT Serif|700|||||||” header_4_font=”PT Serif|700|||||||” header_4_text_color=”#D2C6D2″ header_4_font_size=”26px” header_2_font_size_tablet=”” header_2_font_size_phone=”24px” header_2_font_size_last_edited=”on|phone” header_4_font_size_tablet=”26px” header_4_font_size_phone=”24px” header_4_font_size_last_edited=”on|phone” global_colors_info=”{}”]<\/p>\n

References<\/h4>\n

[\/et_pb_text][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”PT Serif||||||||” text_text_color=”#000000″ text_font_size=”17px” text_line_height=”1.8em” custom_padding=”|||0px||” global_colors_info=”{}”]<\/p>\n

[1] He J., Yu L., Lin X., Liu X., Zhang Y., Yang F., Deng W. 2022. Virus-like particles as nanocarriers for intracellular delivery of biomolecules and compounds. Viruses 14:1905.\u00a0<\/span><\/a><\/p>\n

[2] Korneyenkov M.A., Zamyatnin Jr. A.A. 2021. Next step in gene delivery: modern approaches and further perspectives of AAV tropism modification. Pharmaceutics 13:50.<\/span><\/a><\/p>\n

[3] Srivastava A., Mallela K.M.G., Deorkar N., Brophy G. 2021. Manufacturing challenges and rational formulation development for AAV viral vectors. J. Pharm. Sci. 110:2609-2624.<\/span><\/a><\/p>\n

[4] Deuker D., Asilonu E., Bracewell D.G., Frank S. 2024. Adeno-associated virus 5 protein particles produced by E. coli cell-free protein synthesis. ACS Synth. Biol. 13:2710-2717.\u00a0<\/span><\/a><\/p>\n

[5] Spice A.J., Aw R., Bracewell D.G., Polizzi K.M. 2020. Synthesis and assembly of hepatitis B virus-like particles in a Pichia pastoris cell-free system. Front. Bioeng. Biotechnol. 8:72.<\/span><\/a><\/p>\n

[6] Armero-Gimenez J., Wilbers R., Schots A., Williams C., Finnern R. 2023. Rapid screening and scaled<\/a>
manufacture of immunogenic virus-like particles in a tobacco BY-2 cell-free protein synthesis system. Front. Immunol. 14:1088852.<\/a><\/p>\n

[7] Sheng J., Lei S., Yuan L., Feng X. 2017. Cell-free protein synthesis of norovirus virus-like particles. RSC Adv. 7:28837.<\/a><\/p>\n

[8] Black L.W., Rao V.B. 2012. Structure, assembly, and DNA packaging of the bacteriophage T4 head. Adv. Virus Res. 82:119-153.<\/a><\/p>\n

[9] Garenne D., Bowden S., Noireaux. 2021. Cell-free expression and synthesis of viruses and bacteriophages: applications to medicine and nanotechnology. Curr. Opin. Syst. Biol. 28:100373.<\/a><\/p>\n

[10] Patel K.G., Swartz J.R. 2011. Surface functionalization of virus-like particles by direct conjugation using azide-alkyne click chemistry. Bioconjug. Chem. 22:376-387.<\/a><\/p>\n

[11] Lu Y., Welsh J.P., Chan W., Swartz J.R. 2013. Escherichia coli-based cell free production of flagellin and ordered flagellin display on virus-like particles. Biotechnol. Bioeng. 110:2073-2085.<\/a><\/p>\n

[12] Lu Y., Chan W., Ko B.Y., VanLang C.C., Swartz J.R. 2015. Assessing sequence plasticity of a virus-like nanoparticle by evolution toward a versatile scaffold for vaccines and drug delivery. Proc. Natl. Acad. Sci. 112:12360-12365.<\/a><\/p>\n

[\/et_pb_text][et_pb_divider color=”#D2C6D2″ _builder_version=”4.16″ _module_preset=”default” custom_margin=”60px||||false|false” global_colors_info=”{}”][\/et_pb_divider][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"

Cell-free production of adeno-associated virus protein particles \u2013 Expanded horizons for gene therapy and vaccine development Virus-like proteins (VLPs) are non-infectious polymeric nanoparticles formed from virus-coat proteins but deprived of genetic material. These features have enabled their successful use in several applications such as vaccines, gene therapy, and drug delivery systems [1]. Among the diverse […]<\/p>\n","protected":false},"author":5,"featured_media":5818,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","_surecart_dashboard_logo_width":"180px","_surecart_dashboard_show_logo":true,"_surecart_dashboard_navigation_orders":true,"_surecart_dashboard_navigation_invoices":true,"_surecart_dashboard_navigation_subscriptions":true,"_surecart_dashboard_navigation_downloads":true,"_surecart_dashboard_navigation_billing":true,"_surecart_dashboard_navigation_account":true,"footnotes":""},"categories":[28,32,34,19],"tags":[],"post_folder":[],"class_list":["post-5825","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog-en","category-cell-free-en","category-proteins","category-uncategorized"],"yoast_head":"\nCell-free production of adeno-associated virus protein particles - Synthelis<\/title>\n<meta name=\"description\" content=\"Discover how cell-free systems enable the production of safe, non-infectious VLPs and rAAVs for applications in gene therapy and vaccines\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/synthelis.com\/en\/cell-free-production-of-adeno-associated-virus-protein-particles\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cell-free production of adeno-associated virus protein particles - Synthelis\" \/>\n<meta property=\"og:description\" content=\"Discover how cell-free systems enable the production of safe, non-infectious VLPs and rAAVs for applications in gene therapy and vaccines\" \/>\n<meta property=\"og:url\" content=\"https:\/\/synthelis.com\/en\/cell-free-production-of-adeno-associated-virus-protein-particles\/\" \/>\n<meta property=\"og:site_name\" content=\"Synthelis\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-15T08:46:45+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-28T13:17:12+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/synthelis.com\/wp-content\/uploads\/2025\/05\/AAV-.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"900\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Caroline LOUBIER\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Caroline LOUBIER\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/synthelis.com\/en\/cell-free-production-of-adeno-associated-virus-protein-particles\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/synthelis.com\/en\/cell-free-production-of-adeno-associated-virus-protein-particles\/\"},\"author\":{\"name\":\"Caroline LOUBIER\",\"@id\":\"https:\/\/synthelis.com\/en\/#\/schema\/person\/7173130156a4ecdbb86dcef2a9df3949\"},\"headline\":\"Cell-free production of adeno-associated virus protein particles\",\"datePublished\":\"2025-05-15T08:46:45+00:00\",\"dateModified\":\"2025-05-28T13:17:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/synthelis.com\/en\/cell-free-production-of-adeno-associated-virus-protein-particles\/\"},\"wordCount\":2740,\"image\":{\"@id\":\"https:\/\/synthelis.com\/en\/cell-free-production-of-adeno-associated-virus-protein-particles\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/synthelis.com\/wp-content\/uploads\/2025\/05\/AAV-.webp\",\"articleSection\":[\"Blog\",\"Cell-Free\",\"Proteins\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/synthelis.com\/en\/cell-free-production-of-adeno-associated-virus-protein-particles\/\",\"url\":\"https:\/\/synthelis.com\/en\/cell-free-production-of-adeno-associated-virus-protein-particles\/\",\"name\":\"Cell-free production of adeno-associated virus protein particles - Synthelis\",\"isPartOf\":{\"@id\":\"https:\/\/synthelis.com\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/synthelis.com\/en\/cell-free-production-of-adeno-associated-virus-protein-particles\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/synthelis.com\/en\/cell-free-production-of-adeno-associated-virus-protein-particles\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/synthelis.com\/wp-content\/uploads\/2025\/05\/AAV-.webp\",\"datePublished\":\"2025-05-15T08:46:45+00:00\",\"dateModified\":\"2025-05-28T13:17:12+00:00\",\"author\":{\"@id\":\"https:\/\/synthelis.com\/en\/#\/schema\/person\/7173130156a4ecdbb86dcef2a9df3949\"},\"description\":\"Discover how cell-free systems enable the production of safe, non-infectious VLPs and rAAVs for applications in gene therapy and vaccines\",\"breadcrumb\":{\"@id\":\"https:\/\/synthelis.com\/en\/cell-free-production-of-adeno-associated-virus-protein-particles\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/synthelis.com\/en\/cell-free-production-of-adeno-associated-virus-protein-particles\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/synthelis.com\/en\/cell-free-production-of-adeno-associated-virus-protein-particles\/#primaryimage\",\"url\":\"https:\/\/synthelis.com\/wp-content\/uploads\/2025\/05\/AAV-.webp\",\"contentUrl\":\"https:\/\/synthelis.com\/wp-content\/uploads\/2025\/05\/AAV-.webp\",\"width\":900,\"height\":600,\"caption\":\"adeno-associated virus protein particles -\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/synthelis.com\/en\/cell-free-production-of-adeno-associated-virus-protein-particles\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/synthelis.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cell-free production of adeno-associated virus protein particles\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/synthelis.com\/en\/#website\",\"url\":\"https:\/\/synthelis.com\/en\/\",\"name\":\"Synthelis\",\"description\":\"Biology at speed\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/synthelis.com\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/synthelis.com\/en\/#\/schema\/person\/7173130156a4ecdbb86dcef2a9df3949\",\"name\":\"Caroline LOUBIER\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/874fe5bc2396cb7c1692f499dc8b5afb72caff7b52b8111acc3aa3ae4e65010f?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/874fe5bc2396cb7c1692f499dc8b5afb72caff7b52b8111acc3aa3ae4e65010f?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/874fe5bc2396cb7c1692f499dc8b5afb72caff7b52b8111acc3aa3ae4e65010f?s=96&d=mm&r=g\",\"caption\":\"Caroline LOUBIER\"},\"url\":\"https:\/\/synthelis.com\/en\/author\/caroline\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cell-free production of adeno-associated virus protein particles - Synthelis","description":"Discover how cell-free systems enable the production of safe, non-infectious VLPs and rAAVs for applications in gene therapy and vaccines","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/synthelis.com\/en\/cell-free-production-of-adeno-associated-virus-protein-particles\/","og_locale":"en_US","og_type":"article","og_title":"Cell-free production of adeno-associated virus protein particles - Synthelis","og_description":"Discover how cell-free systems enable the production of safe, non-infectious VLPs and rAAVs for applications in gene therapy and vaccines","og_url":"https:\/\/synthelis.com\/en\/cell-free-production-of-adeno-associated-virus-protein-particles\/","og_site_name":"Synthelis","article_published_time":"2025-05-15T08:46:45+00:00","article_modified_time":"2025-05-28T13:17:12+00:00","og_image":[{"width":900,"height":600,"url":"http:\/\/synthelis.com\/wp-content\/uploads\/2025\/05\/AAV-.webp","type":"image\/webp"}],"author":"Caroline LOUBIER","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Caroline LOUBIER","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/synthelis.com\/en\/cell-free-production-of-adeno-associated-virus-protein-particles\/#article","isPartOf":{"@id":"https:\/\/synthelis.com\/en\/cell-free-production-of-adeno-associated-virus-protein-particles\/"},"author":{"name":"Caroline LOUBIER","@id":"https:\/\/synthelis.com\/en\/#\/schema\/person\/7173130156a4ecdbb86dcef2a9df3949"},"headline":"Cell-free production of adeno-associated virus protein particles","datePublished":"2025-05-15T08:46:45+00:00","dateModified":"2025-05-28T13:17:12+00:00","mainEntityOfPage":{"@id":"https:\/\/synthelis.com\/en\/cell-free-production-of-adeno-associated-virus-protein-particles\/"},"wordCount":2740,"image":{"@id":"https:\/\/synthelis.com\/en\/cell-free-production-of-adeno-associated-virus-protein-particles\/#primaryimage"},"thumbnailUrl":"https:\/\/synthelis.com\/wp-content\/uploads\/2025\/05\/AAV-.webp","articleSection":["Blog","Cell-Free","Proteins"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/synthelis.com\/en\/cell-free-production-of-adeno-associated-virus-protein-particles\/","url":"https:\/\/synthelis.com\/en\/cell-free-production-of-adeno-associated-virus-protein-particles\/","name":"Cell-free production of adeno-associated virus protein particles - Synthelis","isPartOf":{"@id":"https:\/\/synthelis.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/synthelis.com\/en\/cell-free-production-of-adeno-associated-virus-protein-particles\/#primaryimage"},"image":{"@id":"https:\/\/synthelis.com\/en\/cell-free-production-of-adeno-associated-virus-protein-particles\/#primaryimage"},"thumbnailUrl":"https:\/\/synthelis.com\/wp-content\/uploads\/2025\/05\/AAV-.webp","datePublished":"2025-05-15T08:46:45+00:00","dateModified":"2025-05-28T13:17:12+00:00","author":{"@id":"https:\/\/synthelis.com\/en\/#\/schema\/person\/7173130156a4ecdbb86dcef2a9df3949"},"description":"Discover how cell-free systems enable the production of safe, non-infectious VLPs and rAAVs for applications in gene therapy and vaccines","breadcrumb":{"@id":"https:\/\/synthelis.com\/en\/cell-free-production-of-adeno-associated-virus-protein-particles\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/synthelis.com\/en\/cell-free-production-of-adeno-associated-virus-protein-particles\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/synthelis.com\/en\/cell-free-production-of-adeno-associated-virus-protein-particles\/#primaryimage","url":"https:\/\/synthelis.com\/wp-content\/uploads\/2025\/05\/AAV-.webp","contentUrl":"https:\/\/synthelis.com\/wp-content\/uploads\/2025\/05\/AAV-.webp","width":900,"height":600,"caption":"adeno-associated virus protein particles -"},{"@type":"BreadcrumbList","@id":"https:\/\/synthelis.com\/en\/cell-free-production-of-adeno-associated-virus-protein-particles\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/synthelis.com\/en\/"},{"@type":"ListItem","position":2,"name":"Cell-free production of adeno-associated virus protein particles"}]},{"@type":"WebSite","@id":"https:\/\/synthelis.com\/en\/#website","url":"https:\/\/synthelis.com\/en\/","name":"Synthelis","description":"Biology at speed","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/synthelis.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/synthelis.com\/en\/#\/schema\/person\/7173130156a4ecdbb86dcef2a9df3949","name":"Caroline LOUBIER","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/874fe5bc2396cb7c1692f499dc8b5afb72caff7b52b8111acc3aa3ae4e65010f?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/874fe5bc2396cb7c1692f499dc8b5afb72caff7b52b8111acc3aa3ae4e65010f?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/874fe5bc2396cb7c1692f499dc8b5afb72caff7b52b8111acc3aa3ae4e65010f?s=96&d=mm&r=g","caption":"Caroline LOUBIER"},"url":"https:\/\/synthelis.com\/en\/author\/caroline\/"}]}},"_links":{"self":[{"href":"https:\/\/synthelis.com\/en\/wp-json\/wp\/v2\/posts\/5825","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/synthelis.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/synthelis.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/synthelis.com\/en\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/synthelis.com\/en\/wp-json\/wp\/v2\/comments?post=5825"}],"version-history":[{"count":5,"href":"https:\/\/synthelis.com\/en\/wp-json\/wp\/v2\/posts\/5825\/revisions"}],"predecessor-version":[{"id":5938,"href":"https:\/\/synthelis.com\/en\/wp-json\/wp\/v2\/posts\/5825\/revisions\/5938"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/synthelis.com\/en\/wp-json\/wp\/v2\/media\/5818"}],"wp:attachment":[{"href":"https:\/\/synthelis.com\/en\/wp-json\/wp\/v2\/media?parent=5825"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/synthelis.com\/en\/wp-json\/wp\/v2\/categories?post=5825"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/synthelis.com\/en\/wp-json\/wp\/v2\/tags?post=5825"},{"taxonomy":"post_folder","embeddable":true,"href":"https:\/\/synthelis.com\/en\/wp-json\/wp\/v2\/post_folder?post=5825"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}